DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tikosyn (Dofetilide) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. For detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education, see DOSAGE AND ADMINISTRATION.

 

TIKOSYN SUMMARY

TIKOSYN®
(dofetilide)
Capsules

TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties.

TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic.

In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients. (See CLINICAL TRIALS.)

TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.


See all Tikosyn indications & dosage >>

TIKOSYN NEWS HIGHLIGHTS

Published Studies Related to Tikosyn (Dofetilide)

Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. [2007.09.01]

An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. [2006.04]

Phase IV trial evaluating the effectiveness and safety of dofetilide. [2004.07]

The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. [2003.05]

Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy. [2003.02]

more >>

Clinical Trials Related to Tikosyn (Dofetilide)

High Intensity Focused Ultrasound (HIFU) Ablation System Study [Suspended]

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation [Recruiting]

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study [Recruiting]

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial [Recruiting]

more >>

Page last updated: 2007-10-19

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008